Nxera Pharma Co., Ltd.
SOLTF
Price:
$6.1575
Market Cap:
$94.85B
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other n...[Read more]
Industry
Biotechnology
IPO Date
2013-09-04
Stock Exchange
PNK
Ticker
SOLTF
PE Ratio
[-23.68]
ROE
[-5.51%]
Current Ratio
[4.01]
Dividend Yield
[0%]
Enterprise Value
[111.73B]
Dividend History
The ROE as of December 2024 (TTM) for Nxera Pharma Co., Ltd. (SOLTF) is -5.51%
According to Nxera Pharma Co., Ltd.’s latest financial reports and current stock price. The company's current ROE is -5.51%. This represents a change of 294.81% compared to the average of -1.40% of the last 4 quarters.
Nxera Pharma Co., Ltd. (SOLTF) Historical ROE (quarterly & annually)
How has SOLTF ROE performed in the past?
The mean historical ROE of Nxera Pharma Co., Ltd. over the last ten years is 0.37%. The current -5.51% ROE has changed -1592.68% with respect to the historical average. Over the past ten years (40 quarters), SOLTF's ROE was at its highest in in the June 2016 quarter at 37.94%. The ROE was at its lowest in in the March 2016 quarter at -16.26%.
Average
0.37%
Median
1.21%
Minimum
-19.11%
Maximum
33.42%
Nxera Pharma Co., Ltd. (SOLTF) ROE by Quarter and Year
Discovering the peaks and valleys of Nxera Pharma Co., Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 252.06%
Maximum Annual ROE = 33.42%
Minimum Annual Increase = -1732.88%
Minimum Annual ROE = -19.11%
| Year | ROE | Change |
|---|---|---|
| 2023 | -10.77% | -1732.88% |
| 2022 | 0.66% | -62.74% |
| 2021 | 1.77% | -37.32% |
| 2020 | 2.82% | -11.12% |
| 2019 | 3.18% | -116.62% |
| 2018 | -19.11% | 252.06% |
| 2018 | -5.43% | -116.25% |
| 2017 | 33.42% | -599.90% |
| 2016 | -6.68% | -274.13% |
| 2015 | 3.84% | -63.89% |
Nxera Pharma Co., Ltd. (SOLTF) Average ROE
How has SOLTF ROE performed in the past?
The current ROE of Nxera Pharma Co., Ltd. (SOLTF) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-2.78%
5-year avg
-0.47%
10-year avg
0.37%
Nxera Pharma Co., Ltd. (SOLTF) ROE vs. Peers
How is SOLTF’s ROE compared to its peers?
Nxera Pharma Co., Ltd.’s ROE is greater than Gain Therapeutics, Inc. (-203.91%), greater than BioVie Inc. (-188.95%), greater than IN8bio, Inc. (-197.15%), greater than NewAmsterdam Pharma Company N.V. (-53.79%), greater than Cue Biopharma, Inc. (-156.38%), greater than uniQure N.V. (-188.82%), greater than Rocket Pharmaceuticals, Inc. (-62.62%), greater than Rhythm Pharmaceuticals, Inc. (-369.26%), greater than Solid Biosciences Inc. (-58.75%), greater than MeiraGTx Holdings plc (-80.95%), greater than Apellis Pharmaceuticals, Inc. (-103.92%), greater than Blueprint Medicines Corporation (-47.66%), greater than Karuna Therapeutics, Inc. (-25.23%), greater than Mirati Therapeutics, Inc. (-40.45%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than VectivBio Holding AG (-56.92%), less than AVROBIO, Inc. (29.68%), greater than Zura Bio Limited (-39.61%), greater than Elevation Oncology, Inc. (-59.73%), greater than Hepion Pharmaceuticals, Inc. (-505.74%),
| Company | ROE | Market cap |
|---|---|---|
| -203.91% | $42.44M | |
| -188.95% | $39.98M | |
| -197.15% | $18.44M | |
| -53.79% | $2.80B | |
| -156.38% | $68.42M | |
| -188.82% | $864.22M | |
| -62.62% | $1.28B | |
| -369.26% | $3.47B | |
| -58.75% | $174.60M | |
| -80.95% | $477.52M | |
| -103.92% | $4.10B | |
| -47.66% | $5.82B | |
| -25.23% | $12.60B | |
| -40.45% | $4.12B | |
| -22.40% | $1.30B | |
| -56.92% | $1.06B | |
| 29.68% | $5.24M | |
| -39.61% | $174.33M | |
| -59.73% | $35.09M | |
| -505.74% | $3.44M |
Build a custom stock screener for Nxera Pharma Co., Ltd. (SOLTF) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nxera Pharma Co., Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Nxera Pharma Co., Ltd. (SOLTF) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Nxera Pharma Co., Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Nxera Pharma Co., Ltd.'s ROE?
How is the ROE calculated for Nxera Pharma Co., Ltd. (SOLTF)?
What is the highest ROE for Nxera Pharma Co., Ltd. (SOLTF)?
What is the 3-year average ROE for Nxera Pharma Co., Ltd. (SOLTF)?
What is the 5-year average ROE for Nxera Pharma Co., Ltd. (SOLTF)?
How does the current ROE for Nxera Pharma Co., Ltd. (SOLTF) compare to its historical average?